tirzepatide FDA approval date

The FDA approved tirzepatide on 13 May 2022.

FDA approval date
13 May 2022

Drug identity checked against registry records

Included trials

TrialSponsorPhaseStatusPrimary completion
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityNCT06565611PTNPhase 2Active not recruiting2025-02-05Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2022-05-13DaytirzepatideFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA215866", "applicant_as_listed_by_fda": "ELI LILLY AND CO", "brand_names": ["MOUNJARO", "MOUNJARO (AUTOINJECTOR)", "MOUNJARO KWIKPEN"], "active_ingredients": ["TIRZEPATIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20220513", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026